Search-led Peptide Reference
Tesamorelin vs Sermorelin vs CJC-1295: structure and regulatory status
Source-based guide to Tesamorelin vs Sermorelin vs CJC-1295 differences FDA status, with molecular identity, evidence limits, analytical checks and dated regulatory verification.
Direct answer
A useful comparison separates an active ingredient’s approved context from off-label claims, discontinued products and research-only catalog material.
Search engines and AI summaries often collapse aliases, molecule classes, preclinical observations and regulatory events into one confident sentence. A reliable archive record keeps those fields separate and links each claim to a date-stamped primary source.
Name and molecular identity
All three names appear in GHRH-related searches, but they represent distinct molecular constructs and regulatory histories.
Each product needs its own expected mass, reference standard, chromatographic method and impurity profile.
| Identity field | What to verify |
|---|---|
| Name and aliases | Exact spelling, development code and whether an alias is molecule-specific |
| Structure | Sequence or chemical structure, termini, modification and conjugation |
| Molecular form | Free form, salt/counterion, hydration state and calculated mass basis |
| Analytical support | Orthogonal identity, purity, content and lot-linked raw-data references |
How to compare without overclaiming
Compare sequence length, substitutions, conjugation, labeled molecular form, receptor class and jurisdiction-specific approval—not vendor category labels.
Cross-study comparisons require matched populations, models, exposure, duration, endpoints and analysis methods. A receptor label, publication count or high HPLC area percentage cannot by itself establish clinical equivalence, safety, effectiveness or sample identity.
Evidence and status review
Use regulator labeling for approved status, trial registries for investigational uses and primary publications for outcomes. Never transfer evidence from one GHRH analogue to another.
- Start with the exact name and development code in PubMed and a trial registry.
- Separate biochemical, cellular, animal and human evidence.
- Record the jurisdiction and document date for every regulatory claim.
- Open the primary paper or regulator document instead of citing a search snippet.
- Mark missing sequence, method or lot information as unknown rather than inferred.
COA and procurement-document checklist
- Product name, sequence or structure and declared molecular form agree across label, specification and COA.
- Batch number, test date, method identifier and approval/version fields are present.
- Identity, chromatographic purity and net content are reported as different measurements.
- Chromatogram and mass data correspond to the same lot and are reviewable.
- Water, counterion, residual solvent, elemental or endotoxin tests are included when scientifically relevant.
Primary-source verification routes
Statuses and database records change. Save the document date, jurisdiction, registry identifier and access date; use the primary document for consequential claims.